Aduro BioTech Inc (NASDAQ:ADRO) EVP Dirk G. Brockstedt sold 10,000 shares of the business’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $9.40, for a total value of $94,000.00. Following the sale, the executive vice president now directly owns 77,674 shares in the company, valued at $730,135.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Aduro BioTech Inc (NASDAQ ADRO) opened at $8.60 on Wednesday. Aduro BioTech Inc has a 52-week low of $6.01 and a 52-week high of $14.05.
Aduro BioTech (NASDAQ:ADRO) last announced its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). The company had revenue of $3.79 million for the quarter, compared to analyst estimates of $4.04 million. Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same period last year, the firm earned ($0.54) earnings per share. equities analysts predict that Aduro BioTech Inc will post -1.28 EPS for the current year.
Several hedge funds have recently modified their holdings of ADRO. Harvard Management Co. Inc. purchased a new position in shares of Aduro BioTech during the third quarter valued at $69,418,000. JPMorgan Chase & Co. grew its holdings in shares of Aduro BioTech by 283.7% during the second quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock valued at $4,244,000 after buying an additional 275,295 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Aduro BioTech by 762.1% during the first quarter. Renaissance Technologies LLC now owns 181,900 shares of the biotechnology company’s stock valued at $1,955,000 after buying an additional 160,800 shares in the last quarter. Nexthera Capital LP purchased a new position in shares of Aduro BioTech during the second quarter valued at $1,767,000. Finally, Baillie Gifford & Co. grew its holdings in shares of Aduro BioTech by 45.8% during the second quarter. Baillie Gifford & Co. now owns 422,700 shares of the biotechnology company’s stock valued at $4,819,000 after buying an additional 132,700 shares in the last quarter. Institutional investors and hedge funds own 45.19% of the company’s stock.
ADRO has been the topic of a number of recent analyst reports. Oppenheimer initiated coverage on Aduro BioTech in a research report on Monday, October 30th. They set a “buy” rating and a $15.00 target price on the stock. HC Wainwright set a $18.00 target price on Aduro BioTech and gave the stock a “buy” rating in a research report on Tuesday, October 17th. William Blair reaffirmed an “outperform” rating on shares of Aduro BioTech in a research report on Monday, October 2nd. Finally, BidaskClub lowered Aduro BioTech from a “hold” rating to a “sell” rating in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. Aduro BioTech has a consensus rating of “Buy” and an average target price of $19.14.
TRADEMARK VIOLATION WARNING: This piece was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://ledgergazette.com/2017/12/06/dirk-g-brockstedt-sells-10000-shares-of-aduro-biotech-inc-adro-stock.html.
Aduro BioTech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech Inc and related companies with MarketBeat.com's FREE daily email newsletter.